Apolipoprotein M in patients with chronic kidney disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Apolipoprotein M in patients with chronic kidney disease. / Sørensen, Ida MH; Bertelsen, Marianne; Freese, Ellen; Lindhard, Kristine; Ullum, Henrik; Feldt-Rasmussen, Bo; Nielsen, Lars Bo; Christoffersen, Christina; Bro, Susanne.

I: Atherosclerosis, Bind 275, 2018, s. 304-311.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sørensen, IMH, Bertelsen, M, Freese, E, Lindhard, K, Ullum, H, Feldt-Rasmussen, B, Nielsen, LB, Christoffersen, C & Bro, S 2018, 'Apolipoprotein M in patients with chronic kidney disease', Atherosclerosis, bind 275, s. 304-311. https://doi.org/10.1016/j.atherosclerosis.2018.06.815

APA

Sørensen, I. MH., Bertelsen, M., Freese, E., Lindhard, K., Ullum, H., Feldt-Rasmussen, B., ... Bro, S. (2018). Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis, 275, 304-311. https://doi.org/10.1016/j.atherosclerosis.2018.06.815

Vancouver

Sørensen IMH, Bertelsen M, Freese E, Lindhard K, Ullum H, Feldt-Rasmussen B o.a. Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis. 2018;275:304-311. https://doi.org/10.1016/j.atherosclerosis.2018.06.815

Author

Sørensen, Ida MH ; Bertelsen, Marianne ; Freese, Ellen ; Lindhard, Kristine ; Ullum, Henrik ; Feldt-Rasmussen, Bo ; Nielsen, Lars Bo ; Christoffersen, Christina ; Bro, Susanne. / Apolipoprotein M in patients with chronic kidney disease. I: Atherosclerosis. 2018 ; Bind 275. s. 304-311.

Bibtex

@article{72698dbba07a456bb442db7b0b3a1431,
title = "Apolipoprotein M in patients with chronic kidney disease",
abstract = "Background and aims: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Methods: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Results: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease. Conclusions: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.",
keywords = "Cardiovascular risk, Chronic kidney disease, HDL cholesterol, LDL-cholesterol, Plasma apolipoprotein M, Urine apolipoprotein M sphingosine-1-phosphate",
author = "S{\o}rensen, {Ida MH} and Marianne Bertelsen and Ellen Freese and Kristine Lindhard and Henrik Ullum and Bo Feldt-Rasmussen and Nielsen, {Lars Bo} and Christina Christoffersen and Susanne Bro",
year = "2018",
doi = "10.1016/j.atherosclerosis.2018.06.815",
language = "English",
volume = "275",
pages = "304--311",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Apolipoprotein M in patients with chronic kidney disease

AU - Sørensen, Ida MH

AU - Bertelsen, Marianne

AU - Freese, Ellen

AU - Lindhard, Kristine

AU - Ullum, Henrik

AU - Feldt-Rasmussen, Bo

AU - Nielsen, Lars Bo

AU - Christoffersen, Christina

AU - Bro, Susanne

PY - 2018

Y1 - 2018

N2 - Background and aims: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Methods: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Results: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease. Conclusions: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.

AB - Background and aims: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Methods: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Results: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease. Conclusions: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.

KW - Cardiovascular risk

KW - Chronic kidney disease

KW - HDL cholesterol

KW - LDL-cholesterol

KW - Plasma apolipoprotein M

KW - Urine apolipoprotein M sphingosine-1-phosphate

U2 - 10.1016/j.atherosclerosis.2018.06.815

DO - 10.1016/j.atherosclerosis.2018.06.815

M3 - Journal article

C2 - 29980057

AN - SCOPUS:85049320575

VL - 275

SP - 304

EP - 311

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -

ID: 200338738